Could electromagnetic fields help fight breast cancer?
NCT ID NCT07227831
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a device called TheraBionic P1 that sends low-level electromagnetic fields to the body. It is for people with advanced hormone-positive, HER2-negative breast cancer who have already tried standard treatments. The goal is to see if the device can help control the cancer and improve survival, while also checking its safety and tolerability.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TheraBionic P1 device (amplitude-modulated electromagnetic fields)
What this could lead to
If it works, this could offer a new, non-invasive option to help control advanced breast cancer and extend survival when other treatments have stopped working.
What could go wrong
This is an early phase 2 trial with only 82 participants, so results may not apply to everyone. The device is experimental and it is unknown if it will meaningfully improve survival or quality of life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••